Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc.

ALDXNYSE / NASDAQHealthcareSmall cap

$0.84+$0.12 (+16.3%)

Last close · Data as of Nov 20, 2026

Market cap
$106.2M
P/E
-3.1x
EV / EBITDA
-1.6x
Revenue
$0.00
ROCE
-79.7%

This period includes a one-day price step on 17 Mar 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Aldeyra Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+14.4%
3M
-44.0%
6M
-45.8%
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 17 Mar 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 17 Mar 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change +$0.12 (+16.3%) from $0.72 to $0.84 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ALDX, bought on each weekday since 2021.

News & filings

What Aldeyra Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 33.8 million US dollars in fiscal 2025.

Strengths (1)

  • Cash on the balance sheet equals 66% of the company's market value.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.
  • This period includes a one-day price step on 17 Mar 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.

Read moreShow less

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Sector
Healthcare
Shares outstanding
60.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$106.2M
P/E
-3.1x
P/B
2.4x
EV / EBITDA
-1.6x
52-week high
Hidden
52-week low
Hidden

Profitability

ROE
-76.5%
ROCE
-79.7%
ROA
-47.0%

Growth

Revenue
$0.00
Net profit growth, 1Y
-39.4%
Free cash flow
-$33.3M

Solvency

Current ratio
2.58
Debt / Equity
0.35
Debt / Assets
0.22
CFO / Net profit
0.99
Cash / Market cap
66.0%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Aldeyra Therapeutics, Inc. revenue and net profit by fiscal year
Aldeyra Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$62.0M
FY2023$0.00-$37.5M
FY2024$0.00-$55.9M
FY2025$0.00-$33.8M

Cash flows

FY2025: -$33.3M from operations, -$33.3M free after investment (dashed).

Aldeyra Therapeutics, Inc. operating and free cash flow by fiscal year
Aldeyra Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$56.6M-$56.7M
FY2023-$30.3M-$30.3M
FY2024-$43.2M-$43.2M
FY2025-$33.3M-$33.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$31.7M
Net profit
-$33.8M
Cash from operations
-$33.3M
Free cash flow
-$33.3M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$31.7M-$33.8M-$33.3M-76.5%—-39.4%

Monthly returns

Month-by-month returns of ALDX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$72.1M
Liabilities$27.8M
Non-current liabilities$0.00
Equity$44.3M
Paid-in capital$528.1M
Retained earnings-$484.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ALDX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

Not shown (no positive earnings and no EV / Sales): Aldeyra Therapeutics, Inc., Aardvark Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Aldeyra Therapeutics, Inc.ALDXthis company$106.2M-3.1x2.4x-76.5%-1.6x
The Joint Corp.JYNT$117.3M40.3x7.8x19.3%118.2x
Cardiff Oncology, Inc.CRDF$106.0M-2.3x2.3x-101.0%-1.9x
Neuronetics, Inc.STIM$101.6M-2.6x4.5x-174.3%-5.8x
OptimizeRx CorporationOPRX$101.0M19.7x0.8x4.0%6.3x
Definitive Healthcare Corp.DH$95.7M-0.7x0.3x-49.4%-0.7x
Heron Therapeutics, Inc.HRTX$91.5M—6.4x-141.0%—
Outset Medical, Inc.OM$87.7M-1.1x0.7x-64.3%-2.5x
Aardvark Therapeutics, Inc.AARD$86.0M-1.5x0.8x-54.0%-0.6x
Peer median—-1.1x1.6x-59.2%-0.7x

Year-to-date ROI

ALDX since 1 January, against earlier years.

Historical volatility

ALDX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$35.3M
Research and developmentResearch And Development$25.7M
Total expensesTotal Expenses$35.3M
Pretax incomePretax Income-$33.9M

Learn while you research

Academy chapters picked for Aldeyra Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →